olmesartan has been researched along with warfarin in 5 studies
Studies (olmesartan) | Trials (olmesartan) | Recent Studies (post-2010) (olmesartan) | Studies (warfarin) | Trials (warfarin) | Recent Studies (post-2010) (warfarin) |
---|---|---|---|---|---|
841 | 185 | 554 | 36,573 | 2,143 | 14,728 |
Protein | Taxonomy | olmesartan (IC50) | warfarin (IC50) |
---|---|---|---|
Vitamin K epoxide reductase complex subunit 1 | Homo sapiens (human) | 0.0088 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (40.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Honda, K; Izumi, T; Miyaji, Y; Nakayama, S; Okazaki, O; Okudaira, N; Shiosakai, K; Sugiyama, D; Suzuki, W; Takakusa, H; Watanabe, A | 1 |
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Kirch, W; Laeis, P; PĆ¼chler, K | 1 |
Ikeda, T; Kamiyama, E; Kasuya, A; Kurihara, A; Takei, M; Yoshigae, Y | 1 |
5 other study(ies) available for olmesartan and warfarin
Article | Year |
---|---|
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
Topics: Glutathione; Pharmacology; Sulfur Radioisotopes | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction.
Topics: Administration, Oral; Adult; Aluminum Hydroxide; Biological Availability; Blood; Digoxin; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Humans; Hydrolysis; Imidazoles; Injections, Intravenous; Magnesium Hydroxide; Male; Olmesartan Medoxomil; Tetrazoles; Warfarin | 2001 |
Inhibitory effects of angiotensin receptor blockers on CYP2C9 activity in human liver microsomes.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Aryl Hydrocarbon Hydroxylases; Chemical Phenomena; Chemistry, Physical; Cytochrome P-450 CYP2C9; Humans; Hydrogen-Ion Concentration; Hydroxylation; Imidazoles; Microsomes, Liver; Models, Biological; Protein Binding; Structure-Activity Relationship; Tetrazoles; Valine; Valsartan; Warfarin | 2007 |